Psychedelic Therapy Development for Peripartum Disorders

Mark Pollack, MD, outlined expanding clinical programs for luvesilocin across multiple mood and anxiety indications, and reflected on the broader potential of psychedelic agents in psychiatry.

Pollack described 2 active phase 2 trials: one in patients with adjustment disorder with depressed mood in the context of cancer or other serious medical illness and a second in generalized anxiety disorder, initiated in part based on signals of particular benefit in highly anxious patients observed in the postpartum depression study.¹ He framed these programs as following a scientifically grounded trajectory from demonstration studies to confirmatory evidence.

Pollack identified the treatment model offered by psychedelic agents as a potentially transformative shift in the psychiatric pharmacology space. Unlike conventional psychotropics requiring daily administration, luvesilocin and related agents may produce durable benefit after 1 or 2 doses, with some patients potentially requiring only episodic retreatment.² He argued this model carries implications not only for efficacy but for access: "many of these patients will not require ongoing administration of treatment but in some cases can be treated on an as needed basis," meaningfully reducing the burden of chronic medication management.

On mechanism, Pollack described 5-HT2A serotonin receptor engagement as the likely primary driver of effect, producing what he characterized as a rebalancing of brain systems involved in cognition, mood, and anxiety. He expressed optimism that the convergence of mechanistic understanding and emerging clinical data represented "an exciting time to be involved in the study and application of these agents."

Dr Pollack is chief medical officer for Reunion Neuroscience.

References

1. RE104 safety and efficacy study in postpartum depression. Clinical Trials.gov. May 14, 2026. Accessed May 29, 2026. https://clinicaltrials.gov/study/NCT06342310

2. Bryson N, Alexander R, Asnis-Alibozek A, et al. RE104: synthesis and activity of a novel serotonergic psychedelic prodrug of 4-Hydroxy-N,N-diisopropyltryptamine. ACS Chem Neurosci. 2024;15(12):2386-2395.